News Sentiment

RCUS sentiment intelligence

Arcus Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 55 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 27.37 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-5.4% over one week, +12.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -5.4% Price reacting lower
Trend fit Trend active 12.6% over four weeks
Fair value 64.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 30
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 10
Investing.com 4
TradingView 4
simplywall.st 4
MT Newswires 3
Business Wire 2
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 14
Analyst action 4
Deals and strategy 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Benzinga Direct company coverage

Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?

HC Wainwright has increased its price target for Arcus Biosciences (NASDAQ: RCUS) from $32 to $45, while maintaining a Buy rating. This adjustment reflects the company's aggressive expansion into first-line clear cell renal cell carcinoma (ccRCC) development with its drug casdati

Tone
Positive 70/100
Event
Analyst action
Published
20 Jul 2026 19:09
Source
Benzinga
AlphaStreet Direct company coverage

Arcus Biosciences Jumps 5.5% After HC Wainwright & Co. Maintains Buy

Arcus Biosciences (RCUS) saw its stock jump 5.5% to $28.88 on Monday after HC Wainwright & Co. raised its price target from $32 to $45 while maintaining a Buy rating. This bullish analyst action, coupled with increased trading volume, signifies renewed investor confidence in the

Tone
Positive 86/100
Event
Analyst action
Published
20 Jul 2026 17:09
Source
AlphaStreet
Investing.com Canada Direct company coverage

H.C. Wainwright raises Arcus Biosciences stock price target to $45 By Investing.com

H.C. Wainwright has increased its price target for Arcus Biosciences (NASDAQ:RCUS) to $45 from $32, reiterating a Buy rating based on the company's progress in immuno-oncology, particularly with its drug casdatifan for clear cell renal cell carcinoma. The firm highlighted casdati

Tone
Positive 72/100
Event
Analyst action
Published
20 Jul 2026 12:09
Source
Investing.com Canada
Quartr Direct company coverage

Arcus Biosciences (RCUS) Proxy filing Summary

This article summarizes Arcus Biosciences' proxy filing from April 21, 2026, outlining key voting matters for its annual meeting on June 11, 2026. Shareholders are asked to elect four directors, ratify Ernst & Young LLP as the independent auditor, and approve named executive offi

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 22:40
Source
Quartr
Simply Wall Street Direct company coverage

This Insider Has Just Sold Shares In Arcus Biosciences

Arcus Biosciences co-founder and President, Juan Jaen, recently sold approximately US$2.0 million worth of shares at an average price of US$29.63, representing 5.9% of his total holding. While this is the largest insider sale in the past year, it occurred around the current share

Tone
Negative 38/100
Event
Market update
Published
15 Jul 2026 12:10
Source
Simply Wall Street
Investing.com Australia Direct company coverage

Form 4 Arcus Biosciences Inc For: 13 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Arcus Biosciences Inc. on July 13th, 2026. It notes Arcus Biosciences (RCUS) stock price performance and includes general market data for various indices, commodities, and individual stocks. The publication date is sp

Tone
Negative 34/100
Event
Market update
Published
14 Jul 2026 07:44
Source
Investing.com Australia
Market source Direct company coverage

An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run

Jonathan Ponciano reports on an insider sale at Arcus Biosciences, where president Juan C. Jaen sold 68,569 shares through a trust under a Rule 10b5-1 trading plan. Despite the sale, Jaen retains a significant stake of approximately 1.2 million shares. The article emphasizes that

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 Jul 2026 23:09
Source
Market source
Stock Titan Direct company coverage

Arcus Biosciences (RCUS) president trades 68,569 shares under 10b5-1 plan

Arcus Biosciences President Juan C. Jaen reported the sale of 68,569 shares of common stock on July 9-10, 2026, through a trust under a Rule 10b5-1 trading plan. The sales occurred at weighted-average prices between $28.61 and $30.05 per share. Despite these sales, Jaen retains s

Tone
Negative 37/100
Event
Market update
Published
13 Jul 2026 21:41
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 Arcus Biosciences For: 9 July By Investing.com

This article announces the filing of Form 144 for Arcus Biosciences (RCUS) on July 9, by Investing.com. Form 144 filings indicate an intent to sell restricted or control securities. This brief notice provides a direct-to-the-point update regarding this specific financial action r

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 23:11
Source
Investing.com Canada
Stock Titan Direct company coverage

Trust files proposed RCUS Class A sales (RCUS) — multiple dates and amounts

The Juan Carlos Jaen and Anita Galeana 2000 Trust has filed multiple Form 144 notices for proposed sales of Arcus Biosciences (RCUS) Class A Common Stock. These include sales on June 22, 23, 24, and July 9, 2026, totaling numerous shares and significant proceeds. The filing also

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Arcus Biosciences awards stock options to five new employees

Arcus Biosciences (RCUS) announced on July 9, 2026, that its Compensation Committee granted stock options and restricted stock units to five new employees. These inducement awards allow employees to purchase a total of 16,060 shares at $30.26 per share and acquire 8,080 shares of

Tone
Positive 64/100
Event
Market update
Published
09 Jul 2026 20:10
Source
Stock Titan
Quartr Direct company coverage

Arcus Biosciences (RCUS) H.C. Wainwright 27th Annual Global Investment Conference summary

Arcus Biosciences (RCUS) presented at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its pipeline with three programs and five Phase 3 studies, supported by significant financing from partners. A key focus is castatinopathy, a next-generation HIF2α inh

Tone
Positive 72/100
Event
Market update
Published
09 Jul 2026 10:11
Source
Quartr
Sahm Direct company coverage

Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In Focus

Arcus Biosciences (RCUS) is drawing renewed attention following a Nature study on its HIF-2a inhibitor casdatifan, which showed a link between serum EPO suppression and clinical outcomes in metastatic kidney cancer. The company's stock has seen strong recent performance, with a 3

Tone
Positive 66/100
Event
Market update
Published
05 Jul 2026 19:41
Source
Sahm
Sahm Direct company coverage

How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data

Arcus Biosciences' Nature-published ARC-20 study data shows that casdatifan monotherapy for metastatic clear cell renal cell carcinoma links deeper HIF‑2α inhibition to changes in the biomarker serum EPO, with greater EPO suppression associated with higher response rates and long

Tone
Positive 64/100
Event
Macro sensitivity
Published
04 Jul 2026 19:09
Source
Sahm
Stock Titan Direct company coverage

If You Invested $1,000 in Arcus Bioscience (RCUS)

This article analyzes the historical performance of investing $1,000 in Arcus Bioscience (RCUS) over various periods, showing significant returns in the last year but more modest or negative returns over longer durations. It details Arcus Bioscience's focus on developing cancer a

Tone
Positive 60/100
Event
Market update
Published
04 Jul 2026 06:40
Source
Stock Titan
Finviz Direct company coverage

RCUS - Arcus Biosciences Inc Latest SEC Filings

This article provides a snapshot of Arcus Biosciences Inc (RCUS) with its latest financial data, key performance indicators, and market statistics as of July 1, 2026. It covers various metrics including market capitalization, income, sales, insider and institutional ownership, pr

Tone
Negative 42/100
Event
Market update
Published
01 Jul 2026 20:39
Source
Finviz
Stock Titan Direct company coverage

Nature study links a kidney-cancer biomarker to casdatifan benefit

Arcus Biosciences announced new research published in Nature, linking clinical outcomes of patients treated with the HIF-2a inhibitor casdatifan to changes in the biomarker erythropoietin (EPO). The study, ARC-20, showed that deeper suppression of serum EPO correlated with higher

Tone
Positive 74/100
Event
Market update
Published
01 Jul 2026 15:10
Source
Stock Titan
TradingView Direct company coverage

ETFs Investing in Arcus Biosciences, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold shares of Arcus Biosciences, Inc. (RCUS). It provides a detailed table including each ETF's market value, weight of RCUS stock in the fund, issuer, management style, focus, expense ratio, assets under management (A

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 04:40
Source
TradingView
TradingView Direct company coverage

Arcus Biosciences, Inc. Actuals & Estimates (NYSE:RCUS)

This article provides an overview of Arcus Biosciences, Inc. (RCUS) stock performance, analyst estimates, and financial data. It details recent stock price movements, historical highs and lows, market capitalization, and upcoming earnings dates. The company's financial actuals an

Tone
Positive 67/100
Event
Earnings
Published
26 Jun 2026 16:09
Source
TradingView
TradingView Direct company coverage

RCUS Forecast — Price Target — Prediction for 2027

The article provides a forecast for Arcus Biosciences, Inc. (RCUS) stock, including analyst price targets and future predictions. It details the stock's current price, historical performance, earnings reports, revenue, market capitalization, and volatility, along with answers to

Tone
Positive 66/100
Event
Earnings
Published
26 Jun 2026 09:40
Source
TradingView
Stock Titan Direct company coverage

Arcus awards two new employees stock options, RSUs

Arcus Biosciences, a clinical-stage biopharmaceutical company, announced it has granted stock options and restricted stock units to two new employees. These inducement awards, totaling 18,400 options and 9,250 RSUs, were issued under the company's 2020 Inducement Plan, consistent

Tone
Positive 69/100
Event
Market update
Published
25 Jun 2026 15:09
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Arcus Biosciences Inc For: 24 June By Investing.com

This article reports on a Form 4 filing for Arcus Biosciences Inc. on June 24, as published by Investing.com. It indicates that the company's stock symbol is RCUS and that its price has increased by 2.48%. The content is essentially a brief announcement of the filing without furt

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 15:09
Source
Investing.com Nigeria